53 results on '"L. Frantzen"'
Search Results
2. AB0450 Impact of therapeutic patient education on safety skills and infectious events of patients treated by biological dmards in rheumatology: a bi-centric study
- Author
-
L. Frantzen, N. Afif, Christelle Sordet, Laurent Arnaud, L. Sparsa, J. Sibilia, D. Oréfice, M. Ardizzone, and J.-E. Gottenberg
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Arthritis ,Disease cluster ,medicine.disease ,Rheumatology ,Infectious disease (medical specialty) ,Internal medicine ,Therapeutic patient education ,medicine ,Adverse effect ,business ,Prospective cohort study - Abstract
Background Patients treated with biologic DMARDs have to be aware of the specific adverse events and have to be able to manage their treatments in case of infectious disease. Therapeutic Patient Education aims to enable patient to acquire these safety skills. Objectives To assess the impact of Therapeutic Patient Education on safety skills and management of infectious events in patients treated with biologic DMARDs in rheumatology. Methods Bi-centric analytical study comparing safety skills and infectious events between two cohorts of patients (TPE and TPE-naive). Safety skills were assessed by an auto-assessment called “Biosecure”, rated on a scale from 0 to 100. This assessment explores several dimensions of treatment management and was validated for assessment of safety skills in patients treated with biologic DMARDs in rheumatology in a preliminary study. Infectious events and their management were self-reported by patients. A cluster analysis aimed to separate patients into working group based on their shortcomings (on the basis of their answers to the Biosecure Assessment). Results 414 patients answered the assessment. The median Biosecure Score was 70.98/100 (Q1Q3: 60.97–84.63) 47% attended Therapeutic Patient Education. The median Biosecure Score was significantly higher in the TPE group than in the TPE-naive group (74.88 versus 67.20/100; p Cluster analysis based on Biosecure assessment separated patients into 3 level groups but failed to identify specific patient profiles. Conclusions Therapeutic Patient Education could provide better safety skills and better treatment management in patients treated with biologic DMARDs in rheumatology. Prospective studies may confirm the impact of TPE on treatment management during infectious events. Further studies may assess the impact of TPE on incidence of serious infectious events. References [1] Orefice D, Beauvais C, Gossec L, Flipon E, Fautrel B, Marguerie L, et al. Cross-sectional study of self-care safety skills in 677 patients on biodrugs for inflammatory joint disease. Jt Bone Spine Rev Rhum. dec 2014;81(6):502. [2] Rat A-C, Fautrel B, Flipon E, Gossec L, Marguerie L, Nataf H, et al. Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients. Joint Bone Spine. Disclosure of Interest None declared
- Published
- 2018
- Full Text
- View/download PDF
3. FRI0126 Patients’ concerns about and perception of biosimilars in rheumatology : a french survey
- Author
-
Sonia Tropé, Jean-David Cohen, R. Diebold, Morgane Beck, J. Sibilia, A. Munos, Laurent Arnaud, J.-E. Gottenberg, Christelle Sordet, M. Sittler, L. Frantzen, and N. Afif
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Pharmacist ,Biosimilar ,medicine.disease ,Rheumatology ,Patient attitudes ,Internal medicine ,Family medicine ,medicine ,In patient ,Medical prescription ,business ,education ,Rheumatism - Abstract
Background Patient adhesion to biosimilars DMARDs have become a big medico-economic issue. Indeed, savings will depend on penetration rate of biosimilars on the biologics market. Like generics, biosimilars are unknown by the general population and patients reluctance appears to be an obstacle to the diffusion of these therapeutics. Objectives To assess patients‘knowledge, information and concerns about biosimilars and to identify levers and obstacles to adhesion to biosimilars prescription. Methods National cross-sectional study assessing information, knowledge and concerns about biosimilars of french patients treated for a rheumatism (whether they were treated by a bDMARDs or not). The data were collected from march to july 2017 by an online assessment. Results 629 patients answered the assessment. 43% knew the definition of biosimilars. 65% felt unsufficiently informed about biosimilars. The principal sources of information were the rheumatologist and the patient associations. 44% of patients treated with a biosimilar were not informed before they received a biosimilar. Patients concerns focused on molecular structure (46%), efficacy (60%) and tolerance (57%) comparatively to originator bDMARDs. Receiving information about biosimilars and understanding the definition of biosimilarity were two characteristics associated with better adhesion to biosimilars. The rheumatologist was considered the most influent source of information about biosimilar. Patients trust him concerning the decision to switch from the originator biologic to its biosimilar. Patient were reluctant to substitution by the pharmacist (2%). Conclusions Biosimilars are largely unknown by french patients at present. Information seems to be instrumental in patient adhesion to biosimilars and in the preservation of the therapeutic relationship. References [1] Jacobs I, Singh E, Sewell L, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. MAI2016;937. [2] Beck M, Michel B, Rybarczyk-Vigouret M-C, Leveque D, Sordet C, Sibilia J, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs Clin Immunother Biopharm Gene Ther. Dec2016;30(6):585–92. Disclosure of Interest None declared
- Published
- 2018
- Full Text
- View/download PDF
4. Epidemiology and outcome research in CKD 5D
- Author
-
L. Coentrao, C. Ribeiro, C. Santos-Araujo, R. Neto, M. Pestana, W. Kleophas, A. Karaboyas, Y. LI, J. Bommer, R. Pisoni, B. Robinson, F. Port, G. Celik, B. Burcak Annagur, M. Yilmaz, T. Demir, F. Kara, K. Trigka, P. Dousdampanis, N. Vaitsis, S. Aggelakou-Vaitsi, K. Turkmen, I. Guney, F. Turgut, L. Altintepe, H. Z. Tonbul, E. Abdel-Rahman, P. Sclauzero, G. Galli, G. Barbati, M. Carraro, G. O. Panzetta, M. Van Diepen, M. Schroijen, O. Dekkers, F. Dekker, A. Sikole, G. Severova- Andreevska, L. Trajceska, S. Gelev, V. Amitov, S. Pavleska- Kuzmanovska, H. Rayner, R. Vanholder, M. Hecking, B. Jung, M. Leung, F. Huynh, T. Chung, S. Marchuk, M. Kiaii, L. Er, R. Werb, C. Chan-Yan, M. Beaulieu, P. Malindretos, P. Makri, G. Zagkotsis, G. Koutroumbas, G. Loukas, E. Nikolaou, M. Pavlou, E. Gourgoulianni, M. Paparizou, M. Markou, E. Syrgani, C. Syrganis, J. Raimann, L. A. Usvyat, V. Bhalani, N. W. Levin, P. Kotanko, X. Huang, P. Stenvinkel, A. R. Qureshi, U. Riserus, T. Cederholm, P. Barany, O. Heimburger, B. Lindholm, J. J. Carrero, J. H. Chang, J. Y. Sung, J. Y. Jung, H. H. Lee, W. Chung, S. Kim, J. S. Han, K. Y. Na, A. Fragoso, A. Pinho, A. Malho, A. P. Silva, E. Morgado, P. Leao Neves, N. Joki, Y. Tanaka, M. Iwasaki, S. Kubo, T. Hayashi, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, C. Castledine, J. Gilg, C. Rogers, Y. Ben-Shlomo, F. Caskey, J. S. Sandhu, G. S. Bajwa, S. Kansal, J. Sandhu, A. Jayanti, M. Nikam, L. Ebah, A. Summers, S. Mitra, J. Agar, A. Perkins, R. Simmonds, A. Tjipto, S. Amet, V. Launay-Vacher, M. Laville, A. Tricotel, C. Frances, B. Stengel, J.-Y. Gauvrit, N. Grenier, G. Reinhardt, O. Clement, N. Janus, L. Rouillon, G. Choukroun, G. Deray, A. Bernasconi, R. Waisman, A. P. Montoya, A. A. Liste, R. Hermes, G. Muguerza, R. Heguilen, E. L. Iliescu, V. Martina, M. A. Rizzo, P. Magenta, L. Lubatti, G. Rombola, M. Gallieni, C. Loirat, H. Mellerio, M. Labeguerie, B. Andriss, E. Savoye, M. Lassale, C. Jacquelinet, C. Alberti, Y. Aggarwal, J. Baharani, S. Tabrizian, S. Ossareh, M. Zebarjadi, P. Azevedo, F. Travassos, I. Frade, M. Almeida, J. Queiros, F. Silva, A. Cabrita, R. Rodrigues, C. Couchoud, J. Kitty, S. Benedicte, C. Fergus, C. Cecile, B. Sahar, V. Emmanuel, J. Christian, E. Rene, H. Barahimi, M. Mahdavi-Mazdeh, M. Nafar, M. Petruzzi, M. De Benedittis, M. Sciancalepore, L. Gargano, P. Natale, M. C. Vecchio, V. Saglimbene, F. Pellegrini, G. Gentile, P. Stroumza, L. Frantzen, M. Leal, M. Torok, A. Bednarek, J. Dulawa, E. Celia, R. Gelfman, J. Hegbrant, C. Wollheim, S. Palmer, D. W. Johnson, P. J. Ford, J. C. Craig, G. F. Strippoli, M. Ruospo, B. El Hayek, B. Hayek, E. Baamonde, E. Bosch, J. I. Ramirez, G. Perez, A. Ramirez, A. Toledo, M. M. Lago, C. Garcia-Canton, M. D. Checa, B. Canaud, B. Lantz, A. Granger-Vallee, P. Lertdumrongluk, N. Molinari, J. Ethier, M. Jadoul, B. Gillespie, C. Bond, S. Wang, T. Alfieri, P. Braunhofer, B. Newsome, M. Wang, B. Bieber, M. Guidinger, L. Zuo, X. Yu, X. Yang, J. Qian, N. Chen, J. Albert, Y. Yan, S. Ramirez, M. Beresan, A. Lapidus, M. Canteli, A. Tong, B. Manns, J. Craig, G. Strippoli, M. Mortazavi, B. Vahdatpour, S. Shahidi, A. Ghasempour, D. Taheri, S. Dolatkhah, A. Emami Naieni, M. Ghassami, M. Khan, K. Abdulnabi, P. Pai, M. Vecchio, M. A. Muqueet, M. J. Hasan, M. A. Kashem, P. K. Dutta, F. X. Liu, L. Noe, T. Quock, N. Neil, G. Inglese, M. Motamed Najjar, B. Bahmani, A. Shafiabadi, J. Helve, M. Haapio, P.-H. Groop, C. Gronhagen-Riska, P. Finne, R. Sund, M. Cai, S. Baweja, A. Clements, A. Kent, R. Reilly, N. Taylor, S. Holt, L. Mcmahon, M. Carter, F. M. Van der Sande, J. Kooman, R. Malhotra, G. Ouellet, E. L. Penne, S. Thijssen, M. Etter, A. Tashman, A. Guinsburg, A. Grassmann, C. Barth, C. Marelli, D. Marcelli, G. Von Gersdorff, I. Bayh, L. Scatizzi, M. Lam, M. Schaller, T. Toffelmire, Y. Wang, P. Sheppard, L. Neri, V. A. Andreucci, L. A. Rocca-Rey, S. V. Bertoli, D. Brancaccio, G. De Berardis, G. Lucisano, D. Johnson, A. Nicolucci, C. Bonifati, S. D. Navaneethan, V. Montinaro, M. Zsom, A. Bednarek-Skublewska, G. Graziano, J. N. Ferrari, A. Santoro, A. Zucchelli, G. Triolo, S. Maffei, S. De Cosmo, V. M. Manfreda, L. Juillard, A. Rousset, F. Butel, S. Girardot-Seguin, T. Hannedouche, M. Isnard, Y. Berland, P. Vanhille, J.-P. Ortiz, G. Janin, P. Nicoud, M. Touam, E. Bruce, B. Grace, P. Clayton, A. Cass, S. Mcdonald, Y. Furumatsu, T. Kitamura, N. Fujii, S. Ogata, H. Nakamoto, K. Iseki, Y. Tsubakihara, C.-C. Chien, J.-J. Wang, J.-C. Hwang, H.-Y. Wang, W.-C. Kan, N. Kuster, L. Patrier, A.-S. Bargnoux, M. Morena, A.-M. Dupuy, S. Badiou, J.-P. Cristol, J.-M. Desmet, V. Fernandes, F. Collart, N. Spinogatti, J.-M. Pochet, M. Dratwa, E. Goffin, J. Nortier, D. S. Zilisteanu, M. Voiculescu, E. Rusu, C. Achim, R. Bobeica, S. Balanica, T. Atasie, S. Florence, S. Anne-Marie, L. Michel, C. Cyrille, A. Strakosha, N. Pasko, S. Kodra, N. Thereska, A. Lowney, E. Lowney, R. Grant, M. Murphy, L. Casserly, T. O' Brien, W. D. Plant, J. Radic, D. Ljutic, V. Kovacic, M. Radic, K. Dodig-Curkovic, M. Sain, I. Jelicic, T. Hamano, C. Nakano, S. Yonemoto, A. Okuno, M. Katayama, Y. Isaka, M. Nordio, A. Limido, M. Postorino, M. Nichelatti, M. Khil, I. Dudar, V. Khil, I. Shifris, M. Momtaz, A. R. Soliman, M. I. El Lawindi, P. Dzekova-Vidimliski, S. Pavleska-Kuzmanovska, I. Nikolov, G. Selim, T. Shoji, R. Kakiya, N. Tatsumi-Shimomura, Y. Tsujimoto, T. Tabata, H. Shima, K. Mori, S. Fukumoto, H. Tahara, H. Koyama, M. Emoto, E. Ishimura, Y. Nishizawa, and M. Inaba
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Epidemiology ,Medicine ,business ,Intensive care medicine ,Outcome (game theory) - Published
- 2012
- Full Text
- View/download PDF
5. Une infection fongique rare chez un patient immunocompétent
- Author
-
L. Frantzen, F. Mosquera, Jean-Christophe Weber, M. Rondeau-Lutz, C. Martinez, Laboratoire d'Histoire des Sciences et de Philosophie - Archives Henri Poincaré (LHSP), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Archives Henri-Poincaré - Philosophie et Recherches sur les Sciences et les Technologies (AHP-PReST), and Université de Strasbourg (UNISTRA)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
030203 arthritis & rheumatology ,03 medical and health sciences ,0302 clinical medicine ,Gastroenterology ,Internal Medicine ,030204 cardiovascular system & hematology ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,3. Good health - Abstract
Introduction Aspergillus fumigatus est un champignon ubiquitaire, saprophyte qui contamine l’homme au niveau des voies respiratoires. Il n’est generalement responsable d’infection que lorsque les defenses immunitaires sont compromises. L’aspergillose de la base du crâne est une manifestation rare et tres severe de l’aspergillose invasive, atteignant generalement des patients immunodeprimes, pour lesquels un traitement anti-fungique precoce est necessaire. Les spores d’Aspergillus penetrent generalement l’organisme par inhalation et l’atteinte de la base du crâne peut se faire par contiguite ou par dissemination hematogene. Observation Notre patient est adresse pour alteration de l’etat general. Il presente comme principaux antecedents : pacemaker, HTA, AVC ischemique sans sequelle, hyperparathyroidie primaire avec adenome parathyroidien opere, osteoarthrite de la symphyse pubienne. Il decrit depuis quelques jours une asthenie et une fievre. On note depuis quelques semaines la presence d’une dysphonie (atteinte du X ?), d’une dysphagie et d’une sensation d’oreille bouchee a droite. Nous constatons des fausses routes lors de l’hospitalisation et une paralysie a droite du XII, du IX, sans atteinte du XI. Dans ce contexte, un scanner crânien montre une collection hypodense prenant le contraste a sa peripherie de 11 × 12 mm au niveau de la paroi posterieure droite du nasopharynx, avec un processus tissulaire s’etendant en arriere de la partie droite du clivus avec une lyse corticale en regard, un comblement du sinus sphenoidal, une osteite de la base du crâne. Le canal du nerf hypoglosse droit et le foramen jugulaire (lieu de passage du IX, X, XI) sont envahis. Le patient est alors hospitalise en ORL pour biopsie du cavum et sphenoidectomie : la biopsie du cavum retrouve des remaniements necrotiques et inflammatoires aigus avec presence de filaments myceliens. Les examens mycologiques confirment la presence d’A. fumigatus (antigene et culture positive) et l’antigenemie aspergillaire est positive dans le sang (Ag Asp : 0,944). La ponction lombaire realisee par la suite ne montre pas d’argument pour une inflammation du LCR, par contre, l’antigenemie aspergillaire est egalement positive dans le LCR (2,335). Nous concluons donc a une aspergillose sphenoidale droite avec extension a la base du crâne. Un traitement par voriconazole est debute et le patient beneficie egalement d’un nettoyage chirurgical du sinus sphenoidal. Le scanner cerebral de controle montrant une extension des lesions, le traitement anti-fongique est majore avec ajout de caspofungine, avec une amelioration dans les suites. La caspofungine est arretee dans un second temps du fait de la negativation de l’antigenemie aspergillaire (a trois mois de traitement) et amelioration sur les imageries de controle. Le voriconazole a ete poursuivi durant un an. Les troubles neurologiques lies a l’atteinte des paires crâniennes recuperent progressivement et completement en dehors d’une discrete dysphagie. Discussion Generalement, cette atteinte survient chez des patients immunodeprimes. Les comorbidites rapportees sont : neutropenie, hemopathie maligne, transplantation d’organes solides, maladie auto-immune necessitant une corticotherapie. L’âge avance, l’existence d’un cancer ou d’un traitement immunosuppresseur semblent favoriser le developpement d’une atteinte mycotique. Notre patient n’avait aucun facteur de risque ou de cormobidites hormis son âge. Le bilan a la recherche d’une immunodepression sous-jacente est reste negatif dans le cas present (pas de lymphopenie, pas d’hypogammaglobulinemie, analyse fonctionnelle des PNN egalement negative, pas de diabete ni de corticotherapie). Le meilleur examen d’imagerie pour le diagnostic d’osteite de la base du crâne reste l’IRM cerebrale. Cet examen n’a pas etre realise chez notre patient devant ses antecedents (pacemaker). Le traitement comprend deux volets : un traitement chirurgical et medical (anti-fongique). L’anti-fongique de premier choix reste le voriconazole qui penetre bien la barriere hemato-encephalique (le posaconazole reste traitement de sauvetage). La duree de l’antibiotherapie n’est pas codifiee. Les patients ayant eu une prise en charge chirurgicale associee semblent avoir un meilleur pronostic, meme si le pronostic de telles affections est severe. Conclusion L’hypothese d’un cancer du cavum associe ayant favorise l’infection a Aspergillus a ete evoquee, mais non confirmee par les biopsies. La bonne evolution clinique et radiologique sous anti-fongique est en faveur d’une atteinte isolee a Aspergillus. Notre observation est originale par la survenue d’une forme invasive rare d’aspergillose chez un patient a priori immunocompetent, et par l’evolution favorable avec regression complete de l’atteinte des paires crâniennes.
- Published
- 2015
- Full Text
- View/download PDF
6. Acid-base / cell physiology
- Author
-
A. C. Braganca, R. L. M. Moreau, A. C. Seguro, M. H. M. Shimizu, D. A. de Jesus, A. J. Magaldi, A. Baffoun, M. Daiiki, M. A. Youssfi, A. Sayeh, N. Idani, J. Hmida, G. Jean, P. Rieu, D. Joly, L. Frantzen, P. Urena, J. L. Bouchet, M. J. Kim, H. S. Choi, E.-S. Ryu, H.-S. Shin, Y.-J. Choi, D.-H. Kang, O. Kurt, F. Bulucu, M. Cakar, F. Yesildal, H. Sarlak, F. Yesildalildal, S. Kim, J. Lee, N. J. Heo, K. Y. Na, and J. S. Han
- Subjects
Cell physiology ,Transplantation ,Biochemistry ,Nephrology ,business.industry ,Medicine ,Base (exponentiation) ,business - Published
- 2013
- Full Text
- View/download PDF
7. [Reversible posterior encephalopathy syndrome and cardiomyopathy after bevacizumab therapy]
- Author
-
L, Frantzen, M, Rondeau-Lutz, F, Mosquera, C, Martinez, A, Labani, and J C, Weber
- Subjects
Bevacizumab ,Colonic Neoplasms ,Humans ,Female ,Posterior Leukoencephalopathy Syndrome ,Adenocarcinoma ,Cardiomyopathies ,Aged - Abstract
Bevacizumab is an antibody directed against VEGF-A. It is approved for the treatment of many cancer diseases. Its side effects are currently not well known by physicians.A 70-year-old female with metastatic colonic adenocarcinoma was admitted in the intensive care unit because of a coma, four days after having received a combined monthly chemotherapy containing bevacizumab, oxaliplatine, 5 fluorouracil, and folinic acid for the fourth time. On clinical examination, she presented with lower limbs spasticity and hypertension. Etiologic investigations, including cerebral tomodensitometry, cerebrospinal fluid examination, psychotropic drugs urinary testing, and electroencephalogram, were negative. Consciousness improved without any other treatment than nicardipine and urapidil, but the patient was initially confused. Cerebral magnetic resonance imaging showed changes suggestive of posterior reversible encephalopathy syndrome, but also involving frontal lobes. There were additional biological and echocardiographic changes suggestive of cardiac involvement. The patient recovered completely of both cardiac and neurologic manifestations 10 days later.Physicians should be aware of cardiovascular adverse effects of bevacizumab. High blood pressure must be treated to avoid more severe complications. When a posterior reversible encephalopathy syndrome occurs, cardiac involvement should be investigated.
- Published
- 2014
8. Atteinte systémique pulmonaire et rénale lors d’une CIVD sur adénomyose utérine
- Author
-
L. Frantzen, Jean-Christophe Weber, F. Mosquera, M. Rondeau-Lutz, C. Martinez, Institut de recherches interdisciplinaires sur les sciences et la technologie (IRIST), Université de Strasbourg (UNISTRA), Laboratoire d'Histoire des Sciences et de Philosophie - Archives Henri Poincaré (LHSP), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
03 medical and health sciences ,030219 obstetrics & reproductive medicine ,0302 clinical medicine ,Gastroenterology ,Internal Medicine ,030212 general & internal medicine ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,3. Good health - Abstract
Introduction L’association d’une coagulation intravasculaire disseminee (CIVD) a des tumeurs gynecologiques benignes est mal connue des cliniciens. Nous rapportons ici un cas avec atteinte pulmonaire severe et renale. Observation Une patiente de 44 ans, aux antecedents de dysmenorrhees attribuees a un fibrome uterin etait admise pour douleurs abdominales violentes et menorragies. L’examen retrouvait les menorragies abondantes sans autre signe clinique initialement. On notait des elements biologiques en faveur d’une CIVD : taux de prothrombine 23 %, facteur V 19 %, fibrinogene effondre a 0,14 g/L, d -dimeres > 20 000 ng/mL, thrombopenie a 91G/L Le Nadir de l’hemoglobine etait a 7,5 g/dL. On notait aussi des signes de microangiopathie avec elevation des LDH, de la bilirubine libre, et presence de schizocytes sur le frottis sanguin, avec une insuffisance renale organique moderee (clairance a 47 mL/min). La CRP etait a 52 mg/L. Le traitement initial comportait des transfusions de plasma frais congele, de concentres de fibrinogene et 1 g d’acide tranexamique. Un scanner retrouvait un aspect de pneumopathie interstitielle bi-basale, evoquant une stase lymphatique pouvant etre liee soit a une insuffisance cardiaque gauche, soit a une maladie veino-occlusive sans HTAP, et une importante masse uterine evocatrice d’un fibrome. La patiente presentait rapidement une insuffisance respiratoire aigue necessitant une ventilation non invasive en reanimation. Une antibiotherapie par cefotaxime et spiramycine etait introduite. Le bilan d’hemostase se normalisait en quelques jours avec le traitement et la fin de la periode de menstruation, sans necessite de recourir a un traitement chirurgical en urgence. Les signes respiratoires et radiologiques de pneumopathie, l’atteinte renale regressaient concomitamment. L’echocardiographie etait normale, et une IRM pelvienne corrigeait le diagnostic pour une adenomyose diffuse exuberante de 9 cm de diametre, occupant une grande partie du muscle uterin. La patiente etait traitee par analogues de GnRH pour eviter les recidives lors des prochaines menstruations, dans l’attente d’un traitement chirurgical initialement refuse. Discussion L’adenomyose diffuse exuberante est une forme d’endometriose caracterisee par la presence ectopique de muqueuse endometriale dans l’ensemble du myometre. Elle peut etre responsable de dysmenorrhees et de metrorragies. Il a ete decrit des cas de CIVD sur des tumeurs benignes, notamment gynecologiques (fibromes). Quelques rares cas de CIVD sont decrits dans un contexte d’adenomyose, en periode de menstruation [1] , [2] . Dans ces cas, cette association est attribuee a la survenue d’hemorragies intramurales dans le myometre pathologique au cours des menstruations, avec stagnation sanguine responsable de micro-thromboses locales. L’ischemie du myometre provoquerait la liberation de facteur tissulaire responsable de la CIVD. Dans les cas decrits precedemment, les phenomenes micro-thrombotiques semblent plus limites que pour notre cas, avec pour unique defaillance viscerale une alteration moderee de la fonction renale [3] . Chez notre patiente, l’alteration de la fonction renale d’allure organique et une detresse respiratoire avec syndrome interstitiel pulmonaire survenaient de maniere brutale apres la mise en evidence des troubles de coagulation. La biologie mettait en evidence des phenomenes thrombotiques systemiques avec presence de signes d’hemolyse, et de schizocytes, renforcant l’hypothese de l’origine thrombotique de ces defaillances. Concernant l’atteinte pulmonaire interstitielle, nous n’avons pas retenu les 2 autres etiologies possibles : infectieuse devant le caractere peu septique du tableau clinique initial (absence de fievre, absence de signe fonctionnel respiratoire pre-existant a l’atteinte hematologique, CRP peu elevee) ; ou surcharge pulmonaire secondaire a la transfusion de plasma peu probable en l’absence de signe clinique ou echographique. Dans un des cas rapportes, la patiente avait presente des perturbations de la coagulation a minima lors des menstruations suivantes [3] . Conclusion Nous rapportons le cas d’une patiente avec adenomyose exuberante ayant presente une coagulation intravasculaire disseminee avec defaillance renale et pulmonaire en periode de menstruations. La notion de benignite d’un fibrome ou d’une tumeur uterine, s’il ne doit pas empecher de rechercher une autre cause a la CIVD, ne doit pas d’emblee non plus faire rejeter le lien de causalite avec la CIVD et faire discuter rapidement des mesures gynecologiques adequates afin d’eviter de possibles complications graves.
- Published
- 2016
- Full Text
- View/download PDF
9. Physical exercise for cancer patients with advanced disease: a randomized controlled trial
- Author
-
May B. Asp, Ørnulf Paulsen, Jon Håvard Loge, Ingvild Lesteberg, Unni V. Nygaard, Stein Kaasa, Hanne Paltiel, Dagny Faksvåg Haugen, Stian Lydersen, Tone L. Frantzen, Elisabeth Oredalen, Lise Amundsen, Marianne Jensen Hjermstad, and Line Merethe Oldervoll
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Physical exercise ,Disease ,law.invention ,Quality of life ,Randomized controlled trial ,law ,Neoplasms ,Advanced disease ,Medicine ,Humans ,Prospective Studies ,Lost to follow-up ,Prospective cohort study ,Exercise ,Fatigue ,Aged ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Survival Analysis ,Exercise Therapy ,Oncology ,Symptom Management and Supportive Care ,Physical therapy ,Quality of Life ,Female ,Lost to Follow-Up ,business - Abstract
Learning Objectives After completing this course, the reader will be able to: Describe the impact of physical exercise on fatigue and physical performance outcomes in cancer patients with advanced and incurable disease.Identify potential clinical benefits of inclusion of physical exercise in treatment regimens for cancer patients with advanced disease. CME This article is available for continuing medical education credit at CME.TheOncologist.com Background. Physical exercise can improve cancer patients' functioning and reduce their symptom levels. A randomized, controlled trial was launched to test the hypothesis that physical exercise reduces fatigue and improves physical performance in cancer patients with advanced and incurable disease. Methods. Cancer patients (n = 231) with a life expectancy ≤2 years were randomized to a physical exercise group (PEG, n = 121) or a control usual care group (UCG, n = 110). The PEG exercised under supervision 60 minutes twice a week for 8 weeks. Assessments were performed before and after the intervention. The primary outcome was physical fatigue (PF) measured by the Fatigue Questionnaire. Physical performance was a secondary outcome measured by the Shuttle Walk Test (SWT) and hand grip strength (HGS) test. Analyses were performed after multiple imputations for missing data. The trial is registered with ClinicalTrials.gov (identifier, NCT00397774). Findings. Thirty-six percent of the PEG were lost to follow-up compared with 23% of the UCG, primarily as a result of disease progression. Seventy-eight PEG and 85 UCG patients completed the intervention. Analyses showed no significant between-group effects in PF. However, clinically and statistically significant between-group effects were found for the SWT and HGS test. Interpretation. Fatigue was not reduced but physical performance (SWT and HGS test) was significantly improved after 8 weeks of physical exercise. Physical exercise might therefore be a suitable approach for maintaining physical capacity in cancer patients with incurable and advanced disease.
- Published
- 2011
10. PRES avec atteinte cardiaque réversible sous bévacizumab
- Author
-
N. Lora, L. Frantzen, M. Rondeau-Lutz, A. Jenneve, C. Martinez, Jean-Christophe Weber, and F. Mosquera
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Introduction Le bevacizumab, antagoniste du VEGF, est un anticorps monoclonal utilise en association avec differentes chimiotherapies anticancereuses. Ses effets indesirables cardiovasculaires, comme le posterior reversible encephalopathy syndrome (PRES), ne sont pas encore bien connus des cliniciens. Nous rapportons ici un cas de ce type de complication. Observation Une patiente de 70 ans est suivie pour un adenocarcinome colique d’emblee metastatique traite par chimiotherapie. Debut 2014, sa maladie evolue et un traitement par FOLFOX-bevacizumab mensuel est entrepris. La patiente developpe une HTA apres sa premiere cure, pour laquelle est instaure du nebivolol, avec un resultat imparfait sur la tension. Apres sa quatrieme cure, elle presente une dysarthrie, une asthenie et des nausees. Quatre jours plus tard, elle est retrouvee inconsciente. Le score de Glasgow est a 3/15, elle est hypotherme, avec une tension arterielle a 175/88 mmHg. L’examen retrouve une spasticite des membres inferieurs avec hypertonie. Le scanner cerebral retrouve deux hemorragies minimes intraventriculaire et sous-arachnoidienne. A la biologie, on retrouve une rhabdomyolyse (CPK a 12 320 U/L), ainsi qu’une cytolyse et une legere cholestase. A noter une troponine I a 10,12 ( n Discussion Le bevacizumab inhibe les facteurs de croissance endotheliaux, reduisant l’angiogenese et la croissance tumorale. Le PRES est une encephalopathie aigue qui associe cephalees, troubles visuels, confusion, convulsions et hypertension arterielle. Les lesions radiologiques evocatrices sont des hypersignaux de la substance blanche a l’IRM en T2 et FLAIR predominant en parieto-occipital. La physiopathologie associerait des phenomenes d’hyperperfusion cerebrale et de rupture de barriere hemato-encephalique, avec œdeme sous-cortical via l’extravasation de fluides hyperosmotiques. Les principales etiologies en sont l’eclampsie, l’hypertension arterielle, les agents immunosuppresseurs et les agents cytotoxiques. On retrouve dans la litterature quelques cas de PRES sous bevacizumab : ils presentent des particularites cliniques et radiologiques, notamment la plus frequente presence d’une hypertension arterielle (effet secondaire reconnu du bevacizumab), ainsi que l’association a des lesions radiologiques frontales en plus des lesions posterieures [1] , comme chez notre patiente. Dans le cadre du PRES lie au bevacizumab, on suppose que l’anti-VEGF induisant une rarefaction capillaire cerebrale et une alteration de la fonction endotheliale, une hypertension arterielle meme minime pourrait entrainer un œdeme vasogenique cerebral. L’evolution est favorable le plus souvent apres l’arret du traitement. Notre patiente a presente de facon concomitante au PRES, une atteinte cardiaque reversible, consequence des lesions capillaires du bevacizumab, le tableau echographique n’etant pas celui d’un Tako Tsubo. Ces atteintes cardiaques sont decrites [2] mais il ne nous semble pas qu’un PRES avec atteinte reversible de la fonction cardiaque ait ete decrit. Conclusion Le bevacizumab etant de plus en plus utilise, les effets cardiaques et vasculaires doivent etre connus des internistes. En prevention, il faut savoir controler de facon stricte la tension arterielle qui apparait avec le traitement. Lors d’une complication de type PRES, il faut penser a rechercher d’autres atteintes associees, notamment cardiaques.
- Published
- 2014
- Full Text
- View/download PDF
11. Santé bucco-dentaire et mortalité totale et cardiovasculaire chez le patient hémodialysé : ORAL-D une étude de cohorte multinationale
- Author
-
L. Frantzen, Giovanni F.M. Strippoli, S. Trendel, and P. Stroumza
- Subjects
Nephrology - Abstract
Introduction Les affections bucco-dentaires sont plus severes chez les patients dialyses par rapport a la population generale. Pourtant, leur prise en charge est souvent tres limitee. Patients et methodes Dans ORAL-D, une etude de cohorte prospective multinationale, 4320 patients hemodialyses (âge moyen de 61,7 ans et 57,7 % de sexe masculin) ont beneficie d’un examen bucco-dentaire complet et ont ete interroges sur leurs pratiques d’hygiene bucco-dentaire. Nous avons etudie l’association entre sante/hygiene bucco-dentaire et mortalite globale/cardiovasculaire en stratifiant par pays et en ajustant pour l’âge, le sexe, les revenus, le tabagisme, les maladies cardiovasculaires, le diabete, la pression arterielle, le temps passe en dialyse et la phosphoremie. Resultats Durant l’etude (suivi median de 22,1 mois), on denombre 650 deces, dont 325 sont d’origine cardiovasculaire. Apres ajustement, le risque de deces augmente de facon significative chez les 982 (23 % de la cohorte) patients edentes (HR a 1,27 ; IC 95 % de 1,10–1,46). De facon similaire chez les patients non edentes, un score CAO (pour dents Cariees, Absentes ou Obturees) superieur > 12 predit egalement une surmortalite (HR a 1,46 ; IC 95 % de 1,22–1,74). Chez les patients non edentes, le brossage regulier (0,74 ; 0,59–0,94), l’utilisation de fil dentaire (0,49 ; 0,32–0,79), le changement de la brosse a dents au moins tous les 3 mois (0,79 ; 0,66–0,94) et globalement le fait de consacrer de facon quotidienne plus de 2 minutes a son hygiene bucco-dentaire (0,81 ; 0,69–0,95) sont associes a une meilleure survie globale avec des chiffres quasiment superposables pour la mortalite cardiovasculaire. Pour les patients > 60 ans, l’association entre le score CAO et mortalite reste significative mais est un peu plus faible (1,31 ; 1,07–1,60). Discussion et conclusion L’etude ORAL-D met en evidence une association independante entre une moindre sante bucco-dentaire et la mortalite globale et cardiovasculaire chez l’adulte en hemodialyse. D’un autre cote, une bonne hygiene bucco-dentaire est liee a une meilleure survie.
- Published
- 2014
- Full Text
- View/download PDF
12. P-452: Depression and pain: Prevalence, medication and comorbidity in long-term care residents
- Author
-
L. Frantzen, Carine Federspiel, Christiane Theisen-Flies, Jean-Paul Steinmetz, E. Bourkel, and P. Frisch
- Subjects
Long-term care ,medicine.medical_specialty ,business.industry ,National Comorbidity Survey ,medicine ,Geriatrics and Gerontology ,Psychiatry ,medicine.disease ,business ,Gerontology ,Comorbidity ,Depression (differential diagnoses) - Published
- 2015
- Full Text
- View/download PDF
13. Dépression et mortalité cardiovasculaire en hémodialyse : une étude de cohorte multinationale
- Author
-
Patrizia Natale, M. Scaldapane, J.C. Craig, P. Stroumza, V. Saglimbene, L. Gargano, L. Frantzen, Suetonia C. Palmer, J. Dulawa, Giovanni F.M. Strippoli, Marinella Ruospo, and Angelo M. Murgo
- Subjects
Nephrology - Abstract
Introduction La depression est frequente chez les adultes en dialyse avec une prevalence d’environ 25 %. Des etudes montrent un lien entre la depression et la mortalite totale, mais l’association entre la depression et la mortalite cardiovasculaire est incertaine. Patients et methodes Nous avons etudie une cohorte multinationale prospective portant sur les adultes traites par hemodialyse iterative au sein d’un reseau mondial entre avril et novembre 2010. La depression a ete etudiee grâce au Beck Depression Inventory (BDI) II. Les tests de sensibilite considerent un BDI II ≥ 14 pour deceler une depression et BDI II ≥ 20 pour affirmer une depression severe. Le modele de regression de Cox a ete utilise pour evaluer les risques ajustes pour toutes causes et la mortalite cardiovasculaire a 12 mois. Resultats Parmi les 2278 (73 %) participants qui ont fourni des reponses completes aux questions de l’enquete BDI II, 1047 (46 %) des repondants ont signale des symptomes correspondant a la depression. Discussion Les facteurs associes a des symptomes depressifs comprenaient l’âge, le pays, l’emploi, l’education, le tabagisme, la comorbidite cardiovasculaire, la pression arterielle, la dose de dialyse et la prise de medicaments psychoactifs. Au cours du suivi de 11 mois (± 2,5), 175 deces sont survenus, dont 66 etaient attribuables a des causes cardiovasculaires. La depression (BDI ≥ 14) n’etait pas associee a la mortalite toutes causes confondues (HR ajuste 1,26 [IC 95 % de 0,93 a 1,71]) ou a la mortalite cardiovasculaire (0,82 [0,50 a 1,34]). Quand un score plus eleve (BDI ≥ 20) a ete utilise pour identifier la depression, la depression etait associee a une mortalite globale (1,40 [1,02 a 1,93]), tandis qu’une association avec la mortalite cardiovasculaire n’etait pas evidente (1,05 [0,63 a 1,77]). Conclusion La relation entre la depression et la mortalite cardiovasculaire chez les adultes traites par hemodialyse est incertaine. Les liens actuels entre la depression et les causes de mortalite sont influences par les parametres et les seuils utilises pour identifier les symptomes depressifs.
- Published
- 2015
- Full Text
- View/download PDF
14. Lésions buccodentaires chez les patients hémodialysés : ORAL-D, une étude de cohorte multinationale prospective
- Author
-
Patrizia Natale, J. Hegbrant, P. Stroumza, Giovanni F.M. Strippoli, Fabio Pellegrini, D.W. Johnson, Suetonia C. Palmer, L. Gargano, Marinella Ruospo, S. Frantzen-Trendel, L. Frantzen, and V. Saglimbene
- Subjects
Nephrology - Published
- 2013
- Full Text
- View/download PDF
15. Prévalence des lésions buccales chez le patient hémodialysé
- Author
-
S. Frantzen-Trendel, Patrizia Natale, L. Frantzen, P. Stroumza, Marinella Ruospo, Mariacristina Vecchio, M. Le Gall, and Giovanni F.M. Strippoli
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
16. Prévalence de la dysfonction sexuelle chez les patientes traitées par hémodialyse
- Author
-
P. Stroumza, Giovanni F.M. Strippoli, Mariacristina Vecchio, L. Frantzen, and Marinella Ruospo
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
17. La France championne du monde de la consommation de psychotropes… aussi en hémodialyse ?
- Author
-
P. Stroumza, L. Frantzen, and J.-L. Poignet
- Subjects
Nephrology - Published
- 2011
- Full Text
- View/download PDF
18. Parodontite et mortalité totale et cardiovasculaire chez le patient hémodialysé : ORAL-D, une étude de cohorte multinationale
- Author
-
P. Stroumza, L. Frantzen, S. Trendel, and G. Strippoli
- Subjects
Nephrology - Published
- 2014
- Full Text
- View/download PDF
19. Les premiers pas de la posturographie en hémodialyse
- Author
-
S. Mesure, B. Didier, L. Frantzen, and P. Stroumza
- Subjects
Nephrology - Abstract
Introduction En hemodialyse, les chutes presentent un probleme recurrent devant une population vieillissante. La morbi-mortalite inherente a ces chutes est tres importante et leur prevention est donc capitale. Le but de ce travail est d’evaluer la posture sur un echantillon de patients dialyses. La posture est l’elaboration et le maintien actif de la configuration des differents segments du corps dans l’espace. Patients et methodes La posturographie est une methode d’investigation qui evalue a l’aide d’une plate-forme de pression la fonction d’equilibration statique et dynamique du patient. En collaboration avec notre kinesitherapeute et l’Institut des Sciences du Mouvement, nous avons inclus de facon aleatoire 23 patients dialysant depuis plus de 3 mois (12 femmes et 11 hommes, âge moyen de 74,5 ans) avec des mesures posturographiques (les yeux ouverts et fermes) pour les 3 seances de dialyse de la semaine avant et apres chaque seance. Resultats Nous constatons une augmentation (donc une degradation) significative des valeurs posturales des sujets dialyses par rapport aux normes posturographiques habituelles. Cette augmentation se retrouve au niveau de l’ensemble des parametres observables et classiquement reconnus comme representatifs des performances de controle postural des sujets. Ces parametres posturaux sont encore davantage deteriores les yeux fermes, en post-dialyse et lors de la 1 ere seance de la semaine. Discussion et conclusion Nos resultats suggerent que les sujets dialyses presentent une forte instabilite posturale en moyenne avec pour consequence un risque de chute important.
- Published
- 2014
- Full Text
- View/download PDF
20. Electronic maneuvering board and dead reckoning tracer decision aid for the officer of the deck
- Author
-
Joey L. Frantzen, Kenneth L. Ehresman, Riehle, Richard D., and Luqi
- Subjects
Flexibility (engineering) ,Computer science ,business.industry ,Real-time computing ,Navigation system ,System requirements specification ,Ada ,Unified Modeling Language ,General Earth and Planetary Sciences ,Software design ,Use case ,Software engineering ,business ,Software architecture ,computer ,General Environmental Science ,computer.programming_language - Abstract
The U.S. Navy currently bases the majority of our contact management decisions around a time and manning intensive paper-based Maneuvering Board (MOBOARD) process. The use of Maneuvering Boards is a perishable skill that has a steep learning curve. In order to overcome inherent human error, it is not uncommon to have up to four people simultaneously involved in solving just one maneuvering problem. Additional manning requirements are involved on many Naval Ships in order to accurately convey the information to the Officer of the Deck (OOD) and/or the Commanding Officer. When given situations where there exist multiple contacts, the current system is quickly overwhelmed and may not provide Commanding Officers and OODs a complete and accurate picture in a timely manner. The purpose of this research is to implement a stand-alone system that will provide timely and accurate contact information for U.S. Navy Commanding Officers, OODs, and CIC watch teams. By creating a reliable, automated system in a format that is familiar to all Surface Warfare Officers we will provide the Navy with a valuable decision-making tool, while increasing ease of data exchange and reducing current redundancies and manning inefficient practices. Our software design is diagramed using the Unified Modeling Language (UML) with the underlying purpose of implementing an Ada-based system that is neither operating system nor hardware dependent. This approach allows us to develop and implement a design for a wide range of platforms, and will ultimately result in an extremely modular and portable system. Model-View-Controller Additionally, we approached our project using the Model View Controller (MVC). This approach has allowed for flexibility in the current and future use of our core model. Not only does the model meet today's current needs, it is highly extensible and will meet emerging needs for many years to come. In order to meet all of our criterion (i.e. operating system independent and hardware independent) we have implemented our project using GtkAda libraries and a GNAT compiler. Although GNAT makes it possible to link to other languages, we have avoided the use of other languages. This approach has resulted in a robust program that compiles and runs on a wide variety of platforms. The ultimate goal of our thesis is to produce an automated navigation system for the U.S. Navy that will help the Navy to meet reduced manning requirements while increasing the accuracy and reliability of its navigation and contact management systems. The MOBOARD software takes advantage of Ada's capability to separate the system specification from its implementation. In this design, the specification is designed to represent only those features necessary for the required features. That is, designing the context clauses at the specification level, we moved them to the package body so there would be a minimum of dependency on the graphics packages and other platform-specific library units. This approach facilitates a platform-independent presentation of multiple views of the same data. Of particular interest to some Ada practitioners will be our use of the floating-point facilities of Ada 95. We have made extensive use of the floating-point attributes as well as the generic elementary functions package. This was necessary because we are doing a lot of calculations that involve global coordinates, the movement of targets relative to a reference point, navigation calculations, prediction of position, and timing. Ada has proven useful in this project because of its underlying language structure. This structure has allowed us to decompose the software architecture along: 1) A coherent conceptual view 2) A platform-independent module view 3) A maintainable code view 4) A platform-targeted execution view. Each of these views evolves naturally as we progress from the UML use cases through the class and interaction diagrams, and onward to the Ada specifications.
- Published
- 2001
21. État buccodentaire et mortalité globale et cardiovasculaire chez les patients hémodialysés : ORAL-D, une étude de cohorte multinationale prospective
- Author
-
P. Stroumza, Marinella Ruospo, L. Frantzen, Fabio Pellegrini, Giovanni F.M. Strippoli, S. Frantzen-Trendel, and Suetonia C. Palmer
- Subjects
Nephrology - Published
- 2013
- Full Text
- View/download PDF
22. Hygiène buccodentaire, soif et xérostomie chez les patients hémodialysés : ORAL- D, une étude de cohorte multinationale prospective
- Author
-
J. Hegbrant, S. Frantzen-Trendel, P. Stroumza, Patrizia Natale, L. Frantzen, Fabio Pellegrini, Suetonia C. Palmer, V. Saglimbene, Giovanni F.M. Strippoli, and Marinella Ruospo
- Subjects
Nephrology - Published
- 2013
- Full Text
- View/download PDF
23. Dépression chez les patients en hémodialyse : prévalence et corrélation avec la mortalité dans l’étude d’une cohorte multinationale
- Author
-
Eduardo Celia, Suetonia C. Palmer, P. Stroumza, Ruben Gelfman, J. Hegbrant, J. Dulawa, C Del Castillo, Marinella Ruospo, A Bednarek, Giovanni F.M. Strippoli, L. Frantzen, and V. Saglimbene
- Subjects
Nephrology - Published
- 2013
- Full Text
- View/download PDF
24. Dépression et maladies rénales chroniques
- Author
-
Giovanni F.M. Strippoli, P. Stroumza, Mariacristina Vecchio, Marinella Ruospo, and L. Frantzen
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
25. Hémodialyse à domicile : est-ce encore d’actualité ?
- Author
-
Mariacristina Vecchio, Giovanni F.M. Strippoli, Allison Tong, L. Frantzen, L. Gargano, P. Stroumza, and Marinella Ruospo
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
26. Soif et xérostomie chez le patient hémodialysé
- Author
-
M. Le Gall, P. Stroumza, S. Frantzen-Trendel, Patrizia Natale, Marinella Ruospo, Giovanni F.M. Strippoli, Mariacristina Vecchio, and L. Frantzen
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
27. Hygiène buccodentaire chez le patient hémodialysé
- Author
-
P. Stroumza, Giovanni F.M. Strippoli, S. Frantzen-Trendel, L. Frantzen, Patrizia Natale, Mariacristina Vecchio, M. Le Gall, and Marinella Ruospo
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
28. Morbi-mortalité liée aux lésions buccodentaires chez le patient hémodialysé
- Author
-
M. Le Gall, Patrizia Natale, S. Frantzen-Trendel, Marinella Ruospo, Giovanni F.M. Strippoli, L. Frantzen, Mariacristina Vecchio, and P. Stroumza
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
29. Hyperkaliémie et IRC ND/5D : observatoire national des pratiques néphrologiques
- Author
-
R. Joubet, J.-L. Bouchet, P. Rieu, P. Urena, Dominique Joly, L. Frantzen, and Guillaume Jean
- Subjects
Nephrology - Published
- 2012
- Full Text
- View/download PDF
30. Accès à la liste nationale d’attente de transplantation rénale en hémodialyse–collaboration CHU et structure de dialyse privée
- Author
-
J. Labastie Coeyredourq, Y. Saingra, P. Stroumza, L. Frantzen, J.-L. Poignet, M. Lankester, V. Moal, and S. Pascal
- Subjects
Nephrology - Published
- 2011
- Full Text
- View/download PDF
31. Prévention des chutes chez les patients hémodialysés âgés. Bénéfices d’un programme de rééducation avant dialyse
- Author
-
D. Bertrand, P. Stroumza, L. Frantzen, O. Dalco, and J.-L. Poignet
- Subjects
Nephrology - Published
- 2011
- Full Text
- View/download PDF
32. Suivi des évènements indésirables dans 220 centres de dialyse en 2010
- Author
-
S. Schön, Giovanni F.M. Strippoli, P. Stroumza, J. Hegbrant, J.-L. Poignet, and L. Frantzen
- Subjects
Nephrology - Published
- 2011
- Full Text
- View/download PDF
33. État fonctionnel et podologique chez les patients diabétiques dialysés
- Author
-
J.-L. Poignet, Y. Saingra, P. Stroumza, J.-C. Gourheux, M. Lankester, S. Pascal, J. Labastie, and L. Frantzen
- Subjects
Nephrology - Published
- 2011
- Full Text
- View/download PDF
34. Le parvovirus B19 en médecine interne : à propos de quatre observations
- Author
-
A. Pradignac, J.L. Schlienger, Emmanuel Andrès, Fabienne Grunenberger, J.P. Gut, O. Strich, and L Frantzen
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2000
- Full Text
- View/download PDF
35. Home versus in-centre haemodialysis for people with kidney failure.
- Author
-
Cheetham MS, Ethier I, Krishnasamy R, Cho Y, Palmer SC, Johnson DW, Craig JC, Stroumza P, Frantzen L, Hegbrant J, and Strippoli GF
- Subjects
- Humans, Cause of Death, Kidney Failure, Chronic therapy, Kidney Failure, Chronic mortality, Kidney Failure, Chronic complications, Bias, Renal Insufficiency therapy, Renal Insufficiency mortality, Adult, Cardiovascular Diseases mortality, Myocardial Infarction mortality, Stroke mortality, Ambulatory Care Facilities, Hospitalization statistics & numerical data, Non-Randomized Controlled Trials as Topic, Hemodialysis, Home adverse effects, Hemodialysis, Home mortality, Hemodialysis, Home methods, Renal Dialysis adverse effects, Randomized Controlled Trials as Topic, Quality of Life
- Abstract
Background: Home haemodialysis (HHD) may be associated with important clinical, social or economic benefits. However, few randomised controlled trials (RCTs) have evaluated HHD versus in-centre HD (ICHD). The relative benefits and harms of these two HD modalities are uncertain. This is an update of a review first published in 2014. This update includes non-randomised studies of interventions (NRSIs)., Objectives: To evaluate the benefits and harms of HHD versus ICHD in adults with kidney failure., Search Methods: We contacted the Information Specialist and searched the Cochrane Kidney and Transplant Register of Studies up to 9 October 2022 using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. We searched MEDLINE (OVID) and EMBASE (OVID) for NRSIs., Selection Criteria: RCTs and NRSIs evaluating HHD (including community houses and self-care) compared to ICHD in adults with kidney failure were eligible. The outcomes of interest were cardiovascular death, all-cause death, non-fatal myocardial infarction, non-fatal stroke, all-cause hospitalisation, vascular access interventions, central venous catheter insertion/exchange, vascular access infection, parathyroidectomy, wait-listing for a kidney transplant, receipt of a kidney transplant, quality of life (QoL), symptoms related to dialysis therapy, fatigue, recovery time, cost-effectiveness, blood pressure, and left ventricular mass., Data Collection and Analysis: Two authors independently assessed if the studies were eligible and then extracted data. The risk of bias was assessed, and relevant outcomes were extracted. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) or standardised mean difference (SMD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Meta-analysis was performed on outcomes where there was sufficient data., Main Results: From the 1305 records identified, a single cross-over RCT and 39 NRSIs proved eligible for inclusion. These studies were of varying design (prospective cohort, retrospective cohort, cross-sectional) and involved a widely variable number of participants (small single-centre studies to international registry analyses). Studies also varied in the treatment prescription and delivery (e.g. treatment duration, frequency, dialysis machine parameters) and participant characteristics (e.g. time on dialysis). Studies often did not describe these parameters in detail. Although the risk of bias, as assessed by the Newcastle-Ottawa Scale, was generally low for most studies, within the constraints of observational study design, studies were at risk of selection bias and residual confounding. Many study outcomes were reported in ways that did not allow direct comparison or meta-analysis. It is uncertain whether HHD, compared to ICHD, may be associated with a decrease in cardiovascular death (RR 0.92, 95% CI 0.80 to 1.07; 2 NRSIs, 30,900 participants; very low certainty evidence) or all-cause death (RR 0.80, 95% CI 0.67 to 0.95; 9 NRSIs, 58,984 patients; very low certainty evidence). It is also uncertain whether HHD may be associated with a decrease in hospitalisation rate (MD -0.50 admissions per patient-year, 95% CI -0.98 to -0.02; 2 NRSIs, 834 participants; very low certainty evidence), compared with ICHD. Compared with ICHD, it is uncertain whether HHD may be associated with receipt of kidney transplantation (RR 1.28, 95% CI 1.01 to 1.63; 6 NRSIs, 10,910 participants; very low certainty evidence) and a shorter recovery time post-dialysis (MD -2.0 hours, 95% CI -2.73 to -1.28; 2 NRSIs, 348 participants; very low certainty evidence). It remains uncertain if HHD may be associated with decreased systolic blood pressure (SBP) (MD -11.71 mm Hg, 95% CI -21.11 to -2.46; 4 NRSIs, 491 participants; very low certainty evidence) and decreased left ventricular mass index (LVMI) (MD -17.74 g/m
2 , 95% CI -29.60 to -5.89; 2 NRSIs, 130 participants; low certainty evidence). There was insufficient data to evaluate the relative association of HHD and ICHD with fatigue or vascular access outcomes. Patient-reported outcome measures were reported using 18 different measures across 11 studies (QoL: 6 measures; mental health: 3 measures; symptoms: 1 measure; impact and view of health: 6 measures; functional ability: 2 measures). Few studies reported the same measures, which limited the ability to perform meta-analysis or compare outcomes. It is uncertain whether HHD is more cost-effective than ICHD, both in the first (SMD -1.25, 95% CI -2.13 to -0.37; 4 NRSIs, 13,809 participants; very low certainty evidence) and second year of dialysis (SMD -1.47, 95% CI -2.72 to -0.21; 4 NRSIs, 13,809 participants; very low certainty evidence)., Authors' Conclusions: Based on low to very low certainty evidence, HHD, compared with ICHD, has uncertain associations or may be associated with decreased cardiovascular and all-cause death, hospitalisation rate, slower post-dialysis recovery time, and decreased SBP and LVMI. HHD has uncertain cost-effectiveness compared with ICHD in the first and second years of treatment. The majority of studies included in this review were observational and subject to potential selection bias and confounding, especially as patients treated with HHD tended to be younger with fewer comorbidities. Variation from study to study in the choice of outcomes and the way in which they were reported limited the ability to perform meta-analyses. Future research should align outcome measures and metrics with other research in the field in order to allow comparison between studies, establish outcome effects with greater certainty, and avoid research waste., (Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)- Published
- 2024
- Full Text
- View/download PDF
36. 18 F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis.
- Author
-
Kaseb A, Bessac D, Frantzen L, Herber M, Poindron V, and Imperiale A
- Subjects
- Male, Humans, Middle Aged, Radiopharmaceuticals therapeutic use, Magnetic Resonance Imaging, Treatment Outcome, Fluorodeoxyglucose F18, Sarcoidosis diagnostic imaging
- Abstract
Abstract: Spinal cord sarcoidosis (SCS) is an uncommon disease with estimated incidence of 0.4% in patients with systemic sarcoidosis. Spinal cord sarcoidosis typically manifests late in the disease course and significantly contributes to patient morbidity. Therefore, early SCS diagnosis and prompt initiation of therapy are crucial. Herein, we report the case of a 51-year-old man with symptomatic SCS managed by 18 F-FDG PET/MRI, allowing diagnosis and treatment efficacy evaluation of spine involvement. We believe that the increasing clinical availability of hybrid PET/MRI devices will offer new opportunities for optimal management of patients with uncommon severe sarcoidosis localizations, such as nervous system., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Vaccination for Patients Receiving Dialysis.
- Author
-
Sam R, Rankin L, Ulasi I, Frantzen L, Nitsch D, Henner D, Molony D, Wagner J, Chen J, Agarwal SK, Howard A, Atkinson R, Landry D, Pastan SO, and Kalantar-Zadeh K
- Abstract
Vaccinating patients receiving dialysis may prevent morbidity and mortality in this vulnerable population. The National Forum of End-Stage Renal Disease Networks (the Forum) published a revised vaccination toolkit in 2021 to update evidence and recommendations on vaccination for patients receiving dialysis. Significant changes in the last 10 years include more data supporting the use of a high-dose influenza vaccine, the introduction of the Heplisav-B vaccine for hepatitis B, and changes in pneumococcal vaccines, including the approval of the PCV15 and PCV20 to replace the PCV13 and PPSV23 vaccines. Additional key items include the introduction of vaccines against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19), and a new vaccine to prevent respiratory syncytial virus disease. Historically, influenza and pneumococcal vaccinations were routinely administered by dialysis facilities, and because of possible risks of hematogenous spread of hepatitis B, dialysis providers often have detailed hepatitis B vaccine protocols. In March 2021, COVID-19 vaccines were made available for dialysis facilities to administer, although with the end of the public health emergency, vaccine policies by dialysis facilities against COVID-19 remains uncertain. The respiratory syncytial virus vaccine was authorized in 2023, and how dialysis facilities will approach this vaccine also remains uncertain. This review summarizes the Forum's vaccination toolkit and discusses the role of the dialysis facility in vaccinating patients to reduce the risk of severe infections., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
38. Evaluation of Pharmacist Renal Dose Adjustments and Planning for Future Evaluations of Pharmacist Services.
- Author
-
Bassett E, Frantzen L, and Zabel K
- Abstract
Background: Clinical pharmacy services are known to improve patient outcomes. Pharmacists contribute to patient care in the acute care setting in multiple ways, including providing advice and information to patients and the health care team, performing medication histories to prevent waste and support medication adherence, analyzing the cost-effectiveness of medications, and ensuring patient safety through patient monitoring and medication review. Specific clinical pharmacist services include managing intravenous to oral medication adjustments, renal dose adjustments, and performing pharmacokinetic dosing of medications, among others. Many of these clinical services are performed daily but are not evaluated for clinical quality or compliance with policies. Evaluating these clinical services may provide a multitude of benefits to pharmacy departments, health systems, and patients. Methods: The purpose of this study was to evaluate pharmacist use and percent compliance of a renal dose adjustment policy upon initial order verification and discharge. This was completed through retrospective chart review to determine if dose adjustments were made appropriately and descriptive statistics were used to establish pharmacist compliance. Those orders that were inappropriately adjusted were analyzed for trends that could lead to possible policy improvements or pharmacist education opportunities. The completed evaluation also led to the development of an evaluation system that can be utilized to routinely assess clinical pharmacist services. Conclusions: The results of this study are being used to develop and support future clinical service evaluations, inspire process improvements, and improve patient outcomes and pharmacist accountability., Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2020.)
- Published
- 2021
- Full Text
- View/download PDF
39. COVID-19 vaccination in haemodialysis patients: good things come in threes….
- Author
-
Frantzen L, Thibeaut S, Moussi-Frances J, Indreies M, Kiener C, Saingra Y, Santini J, Stroumza P, El-Haik Y, and Cavaillé G
- Subjects
- Humans, Vaccination, COVID-19 prevention & control, COVID-19 Vaccines therapeutic use, Renal Dialysis
- Published
- 2021
- Full Text
- View/download PDF
40. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort.
- Author
-
Frantzen L, Cavaillé G, Thibeaut S, and El-Haik Y
- Subjects
- BNT162 Vaccine, Humans, Vaccines, Synthetic immunology, mRNA Vaccines, COVID-19 prevention & control, COVID-19 Vaccines immunology, Renal Dialysis
- Published
- 2021
- Full Text
- View/download PDF
41. Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control.
- Author
-
O'Connell M, Sandgren M, Frantzen L, Bower E, and Erickson B
- Subjects
- Adult, Aged, Analgesics, Opioid pharmacology, Benzodiazepines pharmacology, Female, Humans, Male, Medical Marijuana pharmacology, Middle Aged, Prospective Studies, Retrospective Studies, Analgesics, Opioid therapeutic use, Benzodiazepines therapeutic use, Medical Marijuana therapeutic use, Pain drug therapy, Pain Management methods
- Abstract
Background: There is currently little evidence regarding the use of medical cannabis for the treatment of intractable pain. Literature published on the subject to date has yielded mixed results concerning the efficacy of medical cannabis and has been limited by study design and regulatory issues. Objective: The objective of this study was to determine if the use of medical cannabis affects the amount of opioids and benzodiazepines used by patients on a daily basis. Methods: This single-center, retrospective cohort study evaluated opioid and benzodiazepine doses over a 6-month time period for patients certified to use medical cannabis for intractable pain. All available daily milligram morphine equivalents (MMEs) and daily diazepam equivalents (DEs) were calculated at baseline and at 3 and 6 months. Results: A total of 77 patients were included in the final analysis. There was a statistically significant decrease in median MME from baseline to 3 months (-32.5 mg; P = 0.013) and 6 months (-39.1 mg; P = 0.001). Additionally, there was a non-statistically significant decrease in median DE at 3 months (-3.75 mg; P = 0.285) and no change in median DE from baseline to 6 months (-0 mg; P = 0.833). Conclusion and Relevance: Over the course of this 6-month retrospective study, patients using medical cannabis for intractable pain experienced a significant reduction in the number of MMEs available to use for pain control. No significant difference was noted in DE from baseline. Further prospective studies are warranted to confirm or deny the opioid-sparing effects of medical cannabis when used to treat intractable pain.
- Published
- 2019
- Full Text
- View/download PDF
42. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
- Author
-
Frantzen L, Cohen JD, Tropé S, Beck M, Munos A, Sittler MA, Diebolt R, Metzler I, and Sordet C
- Subjects
- Adult, Aged, Antirheumatic Agents pharmacology, Arthritis, Rheumatoid diagnosis, Cross-Sectional Studies, Female, France, Humans, Male, Medical Informatics, Middle Aged, Patient Education as Topic, Risk Assessment, Spondylarthritis diagnosis, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Biosimilar Pharmaceuticals therapeutic use, Health Knowledge, Attitudes, Practice, Spondylarthritis drug therapy, Surveys and Questionnaires
- Abstract
Objective: To assess the patients' information about biosimilars and to identify the patients' incentives and deterrents to concur with the use of biosimilars., Methods: Nation-wide cross-sectional study assessing information and concerns about biosimilars of French patients treated for rheumatic inflammatory diseases, whether they were treated or not by a biological DMARD. The assessment was available online from March to July 2017., Results: Among the 629 respondents, 43% knew what biosimilars were. The main sources of information were rheumatologists and patient associations. Among patients treated with a biosimilar, 44% were not informed before they received the treatment. The patients' concerns focused on the non-similar molecular structure (46%), efficacy (60%) and safety (57%) comparatively to the originator biologic. 15% of respondents would refuse to switch their biologic to its biosimilar. More than 50% of respondents would warily accept to switch medications and interrupt the treatment if in doubt. Being informed about biosimilars and a good understanding of the definition of biosimilars were characteristics associated with better adherence to biosimilars. The rheumatologist was considered the most influent source of information about biosimilars and was considered reliable when deciding to switch a biologic to its biosimilar. Patient were reluctant to substitution of the medications by pharmacists (2%). Medico-economical issues acted as an incentive and a deterrent to accept the switch of medication., Conclusion: Biosimilars are largely unknown to patients. Information seems to be instrumental in improving the patients' adherence to biosimilars and could help preserving the therapeutic relationship and avoiding a nocebo effect., (Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
43. Oral mucosal lesions and risk of all-cause and cardiovascular mortality in people treated with long-term haemodialysis: The ORAL-D multinational cohort study.
- Author
-
Ruospo M, Palmer SC, Graziano G, Natale P, Saglimbene V, Petruzzi M, De Benedittis M, Craig JC, Johnson DW, Ford P, Tonelli M, Celia E, Gelfman R, Leal MR, Török M, Stroumza P, Frantzen L, Bednarek-Skublewska A, Dulawa J, Del Castillo D, Schön S, Bernat AG, Hegbrant J, Wollheim C, Gargano L, and Strippoli GFM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases epidemiology, Cause of Death, Cohort Studies, Female, Humans, Internationality, Male, Middle Aged, Mouth Diseases complications, Mouth Diseases mortality, Prevalence, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic therapy, Risk Factors, Young Adult, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Mouth Diseases epidemiology, Renal Dialysis adverse effects, Renal Dialysis mortality, Renal Dialysis statistics & numerical data, Renal Insufficiency, Chronic mortality
- Abstract
Background: Chronic kidney disease is a risk factor for oral diseases, which may be associated with premature death. We evaluated the risk of all-cause and cardiovascular mortality associated with oral mucosal lesions in adults with kidney failure treated with long-term haemodialysis., Methods: Oral mucosal lesions (herpes, ulceration, neoformation, white lesion, red lesion, oral candidiasis, geographical tongue, petechial lesions, and fissured tongue) were evaluated within the Oral Diseases in Haemodialysis (ORAL-D) study, a multinational cohort study of 4726 haemodialysis adults. We conducted cox regression analyses adjusted for demographic and clinical variables to evaluate the association with all-cause and cardiovascular mortality., Results: Overall, 4205 adults (mean age 61.6 ± 15.6 years) underwent oral mucosal examination with 40% affected by at least one lesion. The prevalence of oral lesions was (in order of frequency): oral herpes 0.5%, mucosal ulceration 1.7%, neoformation 2.0%, white lesion 3.5%, red lesion 4.0%, oral candidiasis 4.6%, geographical tongue 4.9%, petechial lesions 7.9%, and fissured tongue 10.7%. During median follow-up of 3.5 years, 2114 patients died (1013 due to cardiovascular disease). No association was observed between any individual oral lesion and all-cause or cardiovascular mortality when adjusted for comorbidities, except for oral candidiasis, which was associated with all-cause mortality (adjusted hazard ratio 1.37, 95% CI 1.00 to 1.86) and cardiovascular mortality (adjusted hazard ratio 1.64, 95% CI 1.09 to 2.46)., Conclusion: Oral mucosal lesions are prevalent in haemodialysis patients. Oral candidiasis appears to be a risk factor for death due to cardiovascular diseases., Competing Interests: MR, PN, VS, EC, RG, MRL, MT, PS, AB-S, JD, LF, JNF, DC, SS, AGB, JH, CW, LG are employees of Diaverum. GS holds a consultancy with Diaverum Renal Services. JH and GS received unrestricted funding from Diaverum Renal Services, a provider of renal services and LCO (Le Cliniche Odontoiatriche, Italy). Funding was used to assist with the cost of oral examination visits in countries where these required specific funding. Funding was also applied to cover overhead costs for study coordinators in each contributing country, material printing and distribution and procurement of standardized examination kits for all patient assessments. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF
44. Periodontitis and early mortality among adults treated with hemodialysis: a multinational propensity-matched cohort study.
- Author
-
Ruospo M, Palmer SC, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Bednarek-Skublewska A, Dulawa J, Frantzen L, Del Castillo D, Schon S, Bernat AG, Hegbrant J, Wollheim C, Gargano L, Bots CP, and Strippoli GF
- Subjects
- Argentina epidemiology, Cardiovascular Diseases diagnosis, Causality, Cohort Studies, Comorbidity, Europe epidemiology, Female, Humans, Incidence, Internationality, Male, Middle Aged, Periodontitis diagnosis, Renal Dialysis statistics & numerical data, Reproducibility of Results, Risk Factors, Sensitivity and Specificity, Survival Rate, Cardiovascular Diseases mortality, Death, Sudden, Cardiac epidemiology, Kidney Failure, Chronic mortality, Kidney Failure, Chronic therapy, Periodontitis mortality, Renal Dialysis mortality
- Abstract
Background: Periodontitis is associated with cardiovascular mortality in the general population and adults with chronic diseases. However, it is unclear whether periodontitis predicts survival in the setting of kidney failure., Methods: ORAL-D was a propensity matched analysis in 3338 dentate adults with end-stage kidney disease treated in a hemodialysis network in Europe and South America designed to examine the association between periodontitis and all-cause and cardiovascular-related mortality in people on long-term hemodialysis. Participants were matched 1:1 on their propensity score for moderate to severe periodontitis assessed using the World Health Organization Community Periodontal Index. A random-effects Cox proportional hazards model was fitted with shared frailty to account for clustering of mortality risk within countries., Results: Among the 3338 dentate participants, 1355 (40.6%) had moderate to severe periodontitis at baseline. After using propensity score methods to generate a matched cohort of participants with periodontitis similar to those with none or mild periodontal disease, moderate to severe periodontitis was associated with a lower risk of all-cause (9.1 versus 13.0 per 100 person years, hazard ratio 0.74, 95% confidence interval 0.61 to 0.90) and cardiovascular (4.3 versus 6.9 per 100 person years, hazard ratio 0.67, 0.51 to 0.88) mortality. These associations were not changed substantially when participants were limited to those with 12 or more natural teeth and when accounting for competing causes of cardiovascular death., Conclusion: In contrast to the general population, periodontitis does not appear to be associated with an increased risk of early death in adults treated with hemodialysis.
- Published
- 2017
- Full Text
- View/download PDF
45. Using Lean to Develop Frontline Clinical Staff Pharmacists as Residency Program Primary Preceptors.
- Author
-
Frantzen L and Ordway B
- Published
- 2017
- Full Text
- View/download PDF
46. Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis.
- Author
-
Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Frantzen L, Bednarek-Skublewska A, Dulawa J, Del Castillo D, Bernat AG, Hegbrant J, Wollheim C, Schon S, Gargano L, Bots CP, and Strippoli GF
- Subjects
- Adolescent, Adult, Aged, Argentina epidemiology, Europe epidemiology, Female, Humans, Internationality, Male, Middle Aged, Mouth Diseases epidemiology, Mouth Diseases etiology, Prevalence, Prospective Studies, Quality of Life, Renal Insufficiency, Chronic therapy, Surveys and Questionnaires, Young Adult, Mouth Diseases diagnosis, Oral Health trends, Renal Dialysis adverse effects, Renal Insufficiency, Chronic complications
- Abstract
Background: Oral disease is a potentially treatable determinant of mortality and quality of life. No comprehensive multinational study to quantify oral disease burden and to identify candidate preventative strategies has been performed in the dialysis setting., Methods: The ORAL disease in hemoDialysis (ORALD) study was a prospective study in adults treated with hemodialysis in Europe (France, Hungary, Italy, Poland, Portugal and Spain) and Argentina. Oral disease was assessed using standardized WHO methods. Participants self-reported oral health practices and symptoms. Sociodemographic and clinical factors associated with oral diseases were determined and assessed within nation states., Results: Of 4726 eligible adults, 4205 (88.9%) participated. Overall, 20.6% were edentulous [95% confidence interval (CI), 19.4-21.8]. Participants had on average 22 (95% CI 21.7-22.2) decayed, missing or filled teeth, while moderate to severe periodontitis affected 40.6% (95% CI 38.9-42.3). Oral disease patterns varied markedly across countries, independent of participant demographics, comorbidity and health practices. Participants in Spain, Poland, Italy and Hungary had the highest mean adjusted odds of edentulousness (2.31, 1.90, 1.90 and 1.54, respectively), while those in Poland, Hungary, Spain and Argentina had the highest odds of ≥14 decayed, missing or filled teeth (23.2, 12.5, 8.14 and 5.23, respectively). Compared with Argentina, adjusted odds ratios for periodontitis were 58.8, 58.3, 27.7, 12.1 and 6.30 for Portugal, Italy, Hungary, France and Poland, respectively. National levels of tobacco consumption, diabetes and child poverty were associated with edentulousness within countries., Conclusions: Oral disease in adults on hemodialysis is very common, frequently severe and highly variable among countries, with much of the variability unexplained by participant characteristics or healthcare. Given the national variation and high burden of disease, strategies to improve oral health in hemodialysis patients will require implementation at a country level rather than at the level of individuals., (© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
47. [Reversible posterior encephalopathy syndrome and cardiomyopathy after bevacizumab therapy].
- Author
-
Frantzen L, Rondeau-Lutz M, Mosquera F, Martinez C, Labani A, and Weber JC
- Subjects
- Adenocarcinoma pathology, Aged, Bevacizumab therapeutic use, Colonic Neoplasms pathology, Female, Humans, Adenocarcinoma drug therapy, Bevacizumab adverse effects, Cardiomyopathies chemically induced, Colonic Neoplasms drug therapy, Posterior Leukoencephalopathy Syndrome chemically induced
- Abstract
Introduction: Bevacizumab is an antibody directed against VEGF-A. It is approved for the treatment of many cancer diseases. Its side effects are currently not well known by physicians., Case Report: A 70-year-old female with metastatic colonic adenocarcinoma was admitted in the intensive care unit because of a coma, four days after having received a combined monthly chemotherapy containing bevacizumab, oxaliplatine, 5 fluorouracil, and folinic acid for the fourth time. On clinical examination, she presented with lower limbs spasticity and hypertension. Etiologic investigations, including cerebral tomodensitometry, cerebrospinal fluid examination, psychotropic drugs urinary testing, and electroencephalogram, were negative. Consciousness improved without any other treatment than nicardipine and urapidil, but the patient was initially confused. Cerebral magnetic resonance imaging showed changes suggestive of posterior reversible encephalopathy syndrome, but also involving frontal lobes. There were additional biological and echocardiographic changes suggestive of cardiac involvement. The patient recovered completely of both cardiac and neurologic manifestations 10 days later., Conclusion: Physicians should be aware of cardiovascular adverse effects of bevacizumab. High blood pressure must be treated to avoid more severe complications. When a posterior reversible encephalopathy syndrome occurs, cardiac involvement should be investigated., (Copyright © 2015 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
48. Dental Health and Mortality in People With End-Stage Kidney Disease Treated With Hemodialysis: A Multinational Cohort Study.
- Author
-
Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Bednarek-Skublewska A, Dulawa J, Frantzen L, Ferrari JN, Del Castillo D, Bernat AG, Hegbrant J, Wollheim C, Gargano L, Bots CP, and Strippoli GF
- Subjects
- Age Factors, Aged, Aged, 80 and over, Cardiovascular Diseases physiopathology, Cohort Studies, Confidence Intervals, Female, Humans, Internationality, Kidney Failure, Chronic diagnosis, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Renal Dialysis methods, Risk Assessment, Sex Factors, Survival Analysis, Treatment Outcome, Cardiovascular Diseases mortality, Cause of Death, Kidney Failure, Chronic mortality, Kidney Failure, Chronic therapy, Oral Health, Renal Dialysis mortality
- Abstract
Background: Dental disease is more extensive in adults with chronic kidney disease, but whether dental health and behaviors are associated with survival in the setting of hemodialysis is unknown., Study Design: Prospective multinational cohort., Setting & Participants: 4,205 adults treated with long-term hemodialysis, 2010 to 2012 (Oral Diseases in Hemodialysis [ORAL-D] Study)., Predictors: Dental health as assessed by a standardized dental examination using World Health Organization guidelines and personal oral care, including edentulousness; decayed, missing, and filled teeth index; teeth brushing and flossing; and dental health consultation., Outcomes: All-cause and cardiovascular mortality at 12 months after dental assessment., Measurements: Multivariable-adjusted Cox proportional hazards regression models fitted with shared frailty to account for clustering of mortality risk within countries., Results: During a mean follow-up of 22.1 months, 942 deaths occurred, including 477 cardiovascular deaths. Edentulousness (adjusted HR, 1.29; 95% CI, 1.10-1.51) and decayed, missing, or filled teeth score ≥ 14 (adjusted HR, 1.70; 95% CI, 1.33-2.17) were associated with early all-cause mortality, while dental flossing, using mouthwash, brushing teeth daily, spending at least 2 minutes on oral hygiene daily, changing a toothbrush at least every 3 months, and visiting a dentist within the past 6 months (adjusted HRs of 0.52 [95% CI, 0.32-0.85], 0.79 [95% CI, 0.64-0.97], 0.76 [95% CI, 0.58-0.99], 0.84 [95% CI, 0.71-0.99], 0.79 [95% CI, 0.65-0.95], and 0.79 [95% CI, 0.65-0.96], respectively) were associated with better survival. Results for cardiovascular mortality were similar., Limitations: Convenience sample of clinics., Conclusions: In adults treated with hemodialysis, poorer dental health was associated with early death, whereas preventive dental health practices were associated with longer survival., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
49. Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study.
- Author
-
Palmer SC, Ruospo M, Campbell KL, Garcia Larsen V, Saglimbene V, Natale P, Gargano L, Craig JC, Johnson DW, Tonelli M, Knight J, Bednarek-Skublewska A, Celia E, Del Castillo D, Dulawa J, Ecder T, Fabricius E, Frazão JM, Gelfman R, Hoischen SH, Schön S, Stroumza P, Timofte D, Török M, Hegbrant J, Wollheim C, Frantzen L, and Strippoli GF
- Subjects
- Adolescent, Adult, Argentina epidemiology, Cause of Death, Energy Intake, Europe epidemiology, Fatty Acids, Omega-3, Fatty Acids, Omega-6, Female, Hospitalization statistics & numerical data, Humans, Infections mortality, Male, Nutritional Status, Prospective Studies, Research Design, Turkey epidemiology, Young Adult, Cardiovascular Diseases mortality, Food, Kidney Failure, Chronic mortality, Kidney Failure, Chronic therapy, Renal Dialysis
- Abstract
Introduction: Adults with end-stage kidney disease (ESKD) treated with haemodialysis experience mortality of between 15% and 20% each year. Effective interventions that improve health outcomes for long-term dialysis patients remain unproven. Novel and testable determinants of health in dialysis are needed. Nutrition and dietary patterns are potential factors influencing health in other health settings that warrant exploration in multinational studies in men and women treated with dialysis. We report the protocol of the "DIETary intake, death and hospitalisation in adults with end-stage kidney disease treated with HaemoDialysis (DIET-HD) study," a multinational prospective cohort study. DIET-HD will describe associations of nutrition and dietary patterns with major health outcomes for adults treated with dialysis in several countries., Methods and Analysis: DIET-HD will recruit approximately 10,000 adults who have ESKD treated by clinics administered by a single dialysis provider in Argentina, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden and Turkey. Recruitment will take place between March 2014 and June 2015. The study has currently recruited 8000 participants who have completed baseline data. Nutritional intake and dietary patterns will be measured using the Global Allergy and Asthma European Network (GA(2)LEN) food frequency questionnaire. The primary dietary exposures will be n-3 and n-6 polyunsaturated fatty acid consumption. The primary outcome will be cardiovascular mortality and secondary outcomes will be all-cause mortality, infection-related mortality and hospitalisation., Ethics and Dissemination: The study is approved by the relevant Ethics Committees in participating countries. All participants will provide written informed consent and be free to withdraw their data at any time. The findings of the study will be disseminated through peer-reviewed journals, conference presentations and to participants via regular newsletters. We expect that the DIET-HD study will inform large pragmatic trials of nutrition or dietary interventions in the setting of advanced kidney disease., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
50. Home versus in-centre haemodialysis for end-stage kidney disease.
- Author
-
Palmer SC, Palmer AR, Craig JC, Johnson DW, Stroumza P, Frantzen L, Leal M, Hoischen S, Hegbrant J, and Strippoli GF
- Subjects
- Adult, Blood Pressure physiology, Humans, Quality of Life, Randomized Controlled Trials as Topic, Time Factors, Hemodialysis, Home adverse effects, Kidney Failure, Chronic therapy, Renal Dialysis adverse effects
- Abstract
Background: Home haemodialysis is associated with improved survival and quality of life in uncontrolled studies. However, relative benefits and harms of home versus in-centre haemodialysis in randomised controlled trials (RCTs) are uncertain., Objectives: To evaluate the benefits and harms of home haemodialysis versus in-centre haemodialysis in adults with end-stage kidney disease (ESKD)., Search Methods: The Cochrane Renal Group's Specialised Register was searched up to 31 October 2014., Selection Criteria: RCTs of home versus in-centre haemodialysis in adults with ESKD were included., Data Collection and Analysis: Data were extracted by two investigators independently. Study risk of bias and other patient-centred outcomes were extracted. Insufficient data were available to conduct meta-analyses., Main Results: We identified a single cross-over RCT (enrolling 9 participants) that compared home haemodialysis (long hours: 6 to 8 hours, 3 times/week) with in-centre haemodialysis (short hours: 3.5 to 4.5 hours, 3 times/weeks) for 8 weeks in prevalent home haemodialysis patients. Outcome data were limited and not available for the end of the first phase of treatment in this cross-over study which was at risk of bias due to differences in dialysate composition between the two treatment comparisons.Overall, home haemodialysis reduced 24 hour ambulatory blood pressure and improved uraemic symptoms, but increased treatment-related burden of disease and interference in social activities. Insufficient data were available for mortality, hospitalisation or dialysis vascular access complications or treatment durability., Authors' Conclusions: Insufficient randomised data were available to determine the effects of home haemodialysis on survival, hospitalisation, and quality of life compared with in-centre haemodialysis. Given the consistently observed benefits of home haemodialysis on quality of life and survival in uncontrolled studies, and the low prevalence of home haemodialysis globally, randomised studies evaluating home haemodialysis would help inform clinical practice and policy.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.